Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
Category: #health  | By Nikita Chaurasia  | Date: 2020-12-07 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab

According to reliable sources, Massachusetts-headquartered clinical stage biopharmaceutical company, Syndax Pharmaceuticals Inc. has revealed an updated data from its Phase 1 trial of its patent axatilimab. The company will reportedly present the data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition and will be available on the company’s official website.

For the uninitiated, axatilimab is an investigational monoclonal antibody developed by Syndax Pharmaceuticals for targeting CSF-1R (colony stimulating factor-1 receptor), a protein that exists on cell surfaces and controls the functioning and survival of macrophages and monocytes. The antibody blocks the development of pulmonary chronic graft-versus-host disease (cGVHD) by mitigating the number of disease-mediating macrophages as well as their monocyte precursors.

The Phase 1 trials enrolled 15 participants, among which 67% patients displayed significant improvements in terms of symptoms, as measured by the Lee Symptom Scale score. Sources confirmed that the patients with refractory diseases were subjected to prior systemic therapies, including belumosudil, ruxolitinib and ibrutinib.

M.D. and CEO of Syndax Pharmaceuticals, Briggs W. Morrison was reported saying that axatilimab is the only agent developed for the treatment of cGVHD which specifically targets the monocyte-macrophage lineage, a key driver of the fibrotic disease process.

If reports are to be believed, Syndax plans on commencing the Phase 2 trials of axatilimab towards the end of 2020 to study the efficacy and safety of different doses of the antibody for treating cGVHD patients. The primary objective of the trials will be to assess the objective response rate based on the 2014 NIH consensus criteria for GVHD.

In other news, U.S.-based multinational pharmaceutical organization, Pfizer Inc. is reportedly planning on establishing an elaborate cold storage set up for maintaining the temperature integrity of its COVID-19 vaccine.

Source credits: https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-announces-additional-positive-data-from-phase-1-trial-of-axatilimab-in-patients-with-cgvhd-301186859.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Reliance Jio to release low-cost laptop with 4G capabilities for $184

Reliance Jio to release low-cost laptop with 4G capabilities for $184

By Nikita Chaurasia

Reliance Jio will reportedly release a budget-friendly laptop with an embedded 4G sim card for $184 (around INR 15,000). The company hopes to build on the success of its low-cost JioPhone in India's fiercely competitive market. The Mukesh...

PM Liz Truss to launch comprehensive review of UK’s visa policy

PM Liz Truss to launch comprehensive review of UK’s visa policy

By Nikita Chaurasia

Newly appointed Prime Minister Liz Truss is considering doing a complete review of Britain's visa system, as the nation struggles with severe labor shortages in vital industries. Business leaders across the UK have reportedly praised the decision...

UAE: Entrepreneurs and investors can benefit from visa reforms

UAE: Entrepreneurs and investors can benefit from visa reforms

By Nikita Chaurasia

The visa and business reforms by the UAE will open new prospects for investors, entrepreneurs, IT specialists, job seekers, and tourists, according to credible sources. This will reportedly benefit the region’s economic growth. Business Link...